Firmoscan
Liquidation12501037Private limited companyBourne End

KYNOS THERAPEUTICS LTD

Significant control: Martin Falk (25–50%)

In liquidationThe company is being wound up. A liquidator deals with its affairs, assets and creditors' claims. Status as shown on the Companies House register at 31 August 2026; it may have changed since. Check the live record.
Companies HouseCompanies House

From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms

Watch this company

Get an email when Companies House records a change for Kynos Therapeutics Ltd: status, filings, accounts, officers or owners. Free.

Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy

Coming soon · product and service lists

What does Kynos Therapeutics Ltd sell?

Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.

One email, only about this. If we don’t launch within 60 days we’ll tell you. Privacy
01

Summary

Generated from filed data · no estimates

KYNOS THERAPEUTICS LTD is a liquidation private limited company (company number 12501037) incorporated on 5 March 2020, registered in Bourne End. Its registered activity is research and experimental development on biotechnology (SIC 72110). Accounts are on file at Companies House (small) but not yet parsed into this record.

There are 50 companies in research and experimental development on biotechnology in Reading with filed accounts; the median reports net assets of £11k and is 7 years old.

02

Ownership and control

1 active · 3 other
  • Dr. Martin Falk
    Individual · since 28 October 2024
    • owns 25–50% of shares
    • holds 25–50% of voting rights
  • Professor Scott Peter Webster
    Individual · since 5 March 2020 · ceased 3 February 2022
    • owns 25–50% of shares
    • holds 25–50% of voting rights
  • Professor Damian James Mole
    Individual · since 5 March 2020 · ceased 3 February 2022
    • owns 25–50% of shares
    • holds 25–50% of voting rights
  • persons with significant control statement · since 5 September 2022 · ceased 28 October 2024

Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.

03

Key dates

Incorporated
5 March 20206 yrs ago
First accounts due
5 December 20211788 days overdue
Confirmation statement due
19 March 2027in 142 days

Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.

04

Activity

SIC 72110
Research and experimental development on biotechnology
Accounts type
Small
05

Financials

No accounts on record

Accounts exist on the register but their figures are not in this dataset yet.

06

Filing and accounts signals

Facts from the register · no rating
  • Incorporated five or more years agoIncorporated 5 March 2020
  • Register status is not ActiveLiquidation

Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.

07

Timeline

Newest first
  1. Confirmation statement duein 142 days
  2. First accounts due1788 days overdue
  3. Incorporated
08

Similar companies in Reading

Same activity (research and experimental development on biotechnology), closest in incorporation date

All companies incorporated on 5 March 2020 · in Mar 2020.

09

Reminders for KYNOS THERAPEUTICS LTD

Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.